Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma
The treatment landscape of advanced melanoma has changed significantly following the discovery and marketing authorisation of immune checkpoints inhibitors. Ipilimumab (anti-CTLA-4) was the first one to be approved, and it. demonstrated long-term survival in about 20% of patients. Subsequently, anti...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2017-03-01
|
| Series: | Contemporary Oncology |
| Subjects: | |
| Online Access: | https://www.termedia.pl/Programmed-cell-death-1-checkpoint-inhibitors-in-the-treatment-of-patients-with-advanced-melanoma,3,29656,1,1.html |